62nd ASH Annual Meeting and Exposition: 703. Adoptive Immunotherapy: Mechanisms and New Approaches: Poster III

Oral and Poster Abstracts
Poster

Adult, ALL, AML, apheresis, Biological, Leukemia, multiple myeloma, Animal models, bioengineering, Diseases, iPSCs, CAR-Ts, Therapies, cellular interactions, checkpoint inhibitors, MDS, Pediatric, B-Cell Lymphoma, Biological Processes, DLBCL, MPN, white blood cells, cell expansion, gene therapy, immune cells, Technology and Procedures, Young Adult, Cell Lineage, immunotherapy, Plasma Cell Disorders, Xenograft models, gene editing, Lymphoid Malignancies, Study Population, Clinically relevant, Myeloid Malignancies, NK cells, imaging, flow cytometry, immune mechanism, transplantation, stem cells, NGS, microenvironment, RNA sequencing, signal transduction

3255

Molecular Imaging of Chimeric Antigen Receptor T Cells By ICOS-Immunopet

Federico Simonetta, MD, PhD¹^*, Israt S. Alam, PhD²^*, Juliane K. Lohmeyer, MD¹^*, Bita Sahaf, PhD³^*, Zinaida Good, PhD³, Weiyu Chen, PhD⁴^*, Zunyu Xiao, MD, PhD⁴^*, Toshihito Hirai, MD, PhD^1,5^*, Lukas Scheller, MD⁶^*, Pujan Engels, M.Sc.⁶^*, Ophir Vermesh, MD, PhD²^*, Elise Robinson⁷^*, Tom Haywood, PhD⁷^*, Ataya Sathirachindra⁷^*, Jeanette Baker¹^*, Meena B. Malipatlolla⁸^*, Liora M. Schultz, MD⁹, Jay Y. Spiegel, MD, FRCPC¹⁰, Jason T. Lee, PhD¹¹^*, David B. Miklos, MD, PhD¹⁰, Crystal L. Mackall, MD^3,12, Sanjiv S. Gambhir, MD, PhD²^* and Robert S. Negrin, MD¹⁰

¹Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University, Stanford, CA
²Department of Radiology, Molecular Imaging Program at Stanford, Stanford University, Stanford, CA
³Center for Cancer Cell Therapy, Stanford University School of Medicine, Stanford, CA
⁴Department of Radiology, Stanford University, Stanford
⁵Department of Urology, Tokyo Women's Medical University, Tokyo, Japan
⁶Stanford University, Stanford, CA
⁷Department of Radiology, Stanford University, Stanford, CA
⁸Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA
⁹Department of Pediatrics, Division of Hematology and Oncology, Stanford University School of Medicine, Palo Alto, CA
¹⁰Division of Blood and Marrow Transplantation, Stanford University, Stanford, CA
¹¹Stanford Center for Innovation in In Vivo Imaging, Stanford University, Stanford, CA
¹²Department of Pediatrics, Division of Hematology and Oncology, Stanford University, Stanford, CA

3256

Efficient Gene Editing of CART Cells with CRISPR-Cas12a for Enhanced Antitumor Efficacy

Elizabeth L. Siegler, PhD^1,2^*, Brandon W Simone³^*, Reona Sakemura, MD, PhD^1,2, Erin E. Tapper^1,2^*, Paulina Horvei, MD^1,4, Michelle J. Cox¹, Mehrdad Hefazi, MD^1,2, Claudia Manriquez Roman^1,2,5,6^*, Ismail Can^1,2,6^*, Kendall J. Schick^1,2,6,7^*, Michael W. Ruff, MD^1,8^*, Stephen C Ekker, PhD³^* and Saad S. Kenderian, MD^1,2,5,9

¹T Cell Engineering, Mayo Clinic, Rochester, MN
²Division of Hematology, Mayo Clinic, Rochester, MN
³Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN
⁴Department of Pediatrics, University of California San Francisco, San Francisco, CA
⁵Department of Molecular Medicine, Mayo Clinic, Rochester, MN
⁶Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN
⁷Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, MN
⁸Department of Neurology, Mayo Clinic, Rochester, MN
⁹Department of Immunology, Mayo Clinic, Rochester, MN

3257

Generation of Natural Killer Cells with Enhanced Function from a CRISPR/Cas12a-Edited Induced Pluripotent Stem Cell Line

Jung-Il Moon, PhD^*, Melissa S Chin, BS^*, Andrew T Burden, BS^*, Steven Sexton^*, Kevin Wasko^*, Jared M Nasser^*, Lincy P Antony^*, Karrie K Wong, PhD, Christopher M Borges, PhD, BS, Richard A. Morgan, PhD and G. Grant Welstead, PhD

Editas Medicine, Cambridge, MA

3258

Preclinical Evaluation of ALLO-605, an Allogeneic BCMA Turbocar T^TM Cell Therapy for the Treatment of Multiple Myeloma

Cesar Sommer, PhD¹, Regina Lin, PhD²^*, Janette Sutton²^*, Trevor Bentley²^*, Duy Nguyen²^*, Hayung Yoon²^*, Melinda Au²^*, Diego Vargas-Inchaustegui, PhD²^*, Hsin-Yuan Cheng, PhD²^*, Tom Van Blarcom²^*, Siler Panowski, PhD² and Barbra Sasu, PhD²

¹Allogene Therapeutics, Inc., San Mateo, CA
²Allogene Therapeutics, Inc., South San Francisco, CA

3259

ATA3219: A Potent Next-Generation Allogeneic Off-the-Shelf CD19-CAR T Therapy without the Need for Gene-Editing

C Pham^*, T Spindler^*, E Hwang^*, A Brito^*, Y Bulliard^* and Blake T Aftab, PhD

Atara Biotherapeutics, Thousand Oaks, CA

3260

First-in-Human Phase I Trial of Adoptive Immunotherapy with Ex Vivo Expanded and Activated Γδ T Cells Following Haploidentical Bone Marrow Transplantation and Post-BMT Cyclophosphamide

Lawrence S. Lamb Jr., PhD¹, Melissa Jo Beelen, Mjbeelen@incysus.com²^*, Samantha Langford Youngblood, BS³^*, Rupal Soder, PhD⁴^*, Sunil Abhyankar, MD⁵ and Joseph P. McGuirk, DO⁶

¹In8bio, Birmingham, AL
²In8bio, New York, NY
³1500 First Avenue North, Suite 103, In8bio, Birmingham, AL
⁴Midwest Stem Cell Therapy Center, Kansas City, KS
⁵Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS
⁶Department of Blood and Bone Marrow Transplant, The University of Kansas Medical Center, Kansas City, KS

3261

Nanobody Based Tri-Specific Chimeric Antigen Receptor to Treat Acute Myeloid Leukaemia

Warren Hazelton, MSc¹^*, Sara Ghorashian, FRCPath, PhD² and Martin Pule, MD PhD³^*

¹Institute of Child Health, University College London, London, United Kingdom
²Developmental Biology and Cancer, UCL Great Ormond Street Institute of Child Health, London, ENG, United Kingdom
³UCL Cancer Institute, London, United Kingdom

3262

Easix As Prediction Score before CAR-T Cells Vs Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Relapsed/Refractory (r/r) Large B Cell Lymphoma (LBCL)

Felix Korell, M.D.^*, Thomas Luft, M.D., PhD, Michael Schmitt, M.D., Sascha Dietrich, M.D., Anita Schmitt, M.D.^*, Carsten Mueller-Tidow, M.D. and Peter Dreger, MD

Internal Medicine V - Hematology, Oncology & Rheumatology, University Hospital Heidelberg, Heidelberg, Germany

3263

Novel Method for Clonal Selection of Multiplexed Engineered CAR-T Cells Which Uniquely Demonstrate Anti-Tumor Functionality in the Tumor Microenvironment

Eigen Peralta, PhD¹^*, David Robbins, BS¹^*, Emily Carron, PhD¹^*, Matthew Denholtz, PhD²^*, Natalie Navarrete, BS¹^*, Dan Lu, PhD¹^*, Joyee Yao¹^*, Sandeep Kothapally Hanok¹^*, Yinghui Sui, PhD¹^*, Angela Gentile¹^*, Eric Sung¹^*, Jason ORourke, PhD¹^*, Tom Lee, PhD¹^*, Daniel Shoemaker, PhD¹, Cokey Nguyen, PhD¹^* and Bahram Valamehr, PhD¹

¹Fate Therapeutics, Inc., San Diego, CA
²Fate Therapeutics Inc., San Diego, CA

3264

Fully Human Tandem CD22-CD19 CAR-T Cells with Superior Sensitivity to Low Antigen Density Derived by Optimization of Co-Stimulation and CAR Architecture

Peirong Hu, PhD^*, Ying Xiong, PhD^*, Darong Wu, MS^*, Zhongyu Zhu, PhD^*, Boro Dropulic, PhD, MBA^* and Dina Schneider, PhD

Lentigen Technology, Inc., a Miltenyi Biotec Company, Gaithersburg, MD

3265

A Shared SF3B1 Neoantigen Is Presented on Primary Malignant Cells and Induced Pluripotent Stem Cell-Derived Hematopoietic Lines

Melinda Ann Biernacki, MD^1,2^*, Kimberly A Foster³^*, Courtnee Clough^4,5, Stephanie Busch, B.S.⁵^*, Carrie Cummings³^*, Vivian G. Oehler, MD^6,7, Derek Stirewalt, MD^1,8^*, Sergei Doulatov, PhD⁹ and Marie Bleakley, MBBS MMSc PhD^2,3

¹Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
²University of Washington, Seattle, WA
³Fred Hutchinson Cancer Research Center, Seattle, WA
⁴Molecular and Cellular Biology Program, University of Washington, Seattle, WA
⁵Division of Hematology, University of Washington, Seattle, WA
⁶Clinical Research Division, Fred Hutchinson Cancer Research Ctr., Seattle, WA
⁷Department of Medicine, University of Washington, Seattle, WA
⁸Departments of Oncology and Hematology, University of Washington, Seattle, WA
⁹Division of Hematology, University of Washington School of Medicine, Seattle, WA

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH